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Abstract
Estrogen-mediated proliferation is fundamental to normal mammary
gland development. Recent studies have demonstrated that
amphiregulin is a critical paracrine regulator of estrogen action
during ductal morphogenesis. These studies implicate a critical
role for amphiregulin in mammary stem cell differentiation as well
as breast cancer initiation and progression.
Introduction
Mammary gland development is a unique, orchestrated
process that primarily occurs postnatally. At the onset of
puberty, circulating ovarian steroid hormones act as pivotal
mediators of ductal morphogenesis. Previous studies using
estrogen receptor knockout mice revealed that estrogen
receptor (ER)α signaling is required for ductal elongation,
which occurs through the proliferation of terminal end buds [1].
More recently, Cathrin Brisken and colleagues [2] performed a
series of elegant transplantation experiments to demonstrate
that estrogen facilitates epithelial proliferation and morpho-
genesis by a paracrine mechanism. Specifically, ERα-null
LacZ+ epithelial cells were mixed with wild-type (WT) epithelial
cells and transplanted into the cleared fat pads of WT mice.
More than half of the resulting outgrowths were chimeric,
indicating that the presence of WT epithelial cells could rescue
the ERα-null phenotype. Brisken and coworkers [2] hypothe-
sized that estrogens stimulate a subset of ductal cells, which in
turn secrete paracrine factors that allow neighboring cells to
proliferate and contribute to ductal outgrowth. This postulate
raises the following critical question: what is the mechanism(s)
by which estrogens induce ductal epithelial proliferation? The
answer to this question has direct implications for our
understanding of both stem cell biology and hormone-
dependent/independent breast cancer proliferation.
Amphiregulin as a paracrine mediator of
estrogen-induced ductal morphogenesis
Several candidate paracrine factors have been suggested to
regulate hormone-induced proliferation and morphogenesis,
including Wnt-4, receptor activator of NFκB ligand (RANKL),
growth hormone and insulin growth factor II (reviewed in [3]).
With regard to estrogen action, however, amphiregulin
(AREG) appears to be the major paracrine mediator of ductal
morphogenesis [4]. AREG is a member of the epidermal
growth factor receptor (EGFR) family of ligands that binds
exclusively to EGFR (ErbB1). Unlike the other EGFR ligands,
AREG is upregulated in the mammary gland during ductal
elongation, rendering this growth factor a likely mediator of
epithelial proliferation. Furthermore, ductal outgrowth is
severely impaired in AREG-/- mice, similar to the phenotype
displayed by ERα-null mammary glands. Brisken and
colleagues recently demonstrated that AREG mRNA levels
are increased in response to estrogen in the puberal
mammary gland and that this increase is mediated by ERα
[4]. Analysis of AREG-null mammary glands at various
developmental stages showed that AREG is essential for
ductal elongation as well as estrogen-induced proliferation
and terminal end bud formation. Additionally, GFP-tagged
AREG-null mammary tissue transplanted into the cleared fat
pads of WT mice failed to grow. Elegant chimeric
transplantation experiments were again utilized to investigate
whether AREG elicited a paracrine response. Strikingly,
grafting of mosaic epithelia containing both AREG-null and
WT cells recapitulated the phenotype exhibited by ERα
chimeric glands. AREG-null epithelial cells were able to
proliferate only when WT cells resided nearby, supporting the
notion that AREG is an important paracrine regulator of
estrogen-induced proliferation [4].
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Notably, previous studies have shown that EGFR in the
stroma, but not the epithelium, is essential for ductal
morphogenesis [5,6]. Studies by Werb and coworkers
revealed a potential mechanism by which epithelial-derived
AREG activates EGFR on neighboring stromal cells [7]. They
demonstrated that in culture, ADAM17 (a disintegrin and
metalloproteinase 17) activates AREG, which is normally
secreted as an inactive, transmembrane precursor [7]. Similar
to the phenotype observed in AREG-null mammary glands,
ductal outgrowth was inhibited in ADAM17-/- epithelium, and
exogenous AREG could rescue ADAM17-/- transplants [7].
These data suggest a key role for ADAM17 in the paracrine
interaction elicited by estrogen signaling.
While intriguing, these results raise several critical questions.
First, is AREG necessary and sufficient to rescue ductal
morphogenesis in ERα-null mammary epithelium, or are other
paracrine factors involved? These types of genetic rescue
experiments are required to validate the models proposed by
Brisken and Werb and colleagues. Second, how does AREG
signal through the basement membrane and the
myoepithelium to act on EGFR in the stroma? Likewise, what
is the reciprocal paracrine signal that stimulates the
epithelium? Stromal-derived fibroblast growth factor 7 has
been suggested to activate epithelial fibroblast growth factor
receptor 2b during mammary branching [3], but genetic
evidence for this mechanism has yet to be provided.
Estrogen receptor-α α and mammary stem cells
What insights do these studies provide with respect to the
potential role of estrogen-mediated proliferation in mammary
stem cells? Although considerable progress has been made
in the characterization of mammary stem cells, the mecha-
nisms that regulate their self-renewal remain poorly under-
stood. Previous studies involving the role of steroid hormones
in stem/progenitor cell activity have reported conflicting
results. It has been proposed that slow-dividing, label-
retaining ERα-positive cells comprise a stem/progenitor cell
population that can directly respond to hormones [8,9]. In
striking contrast, Brisken and colleagues’ studies suggest
that non-proliferating ERα-positive cells exploit a paracrine
mechanism to stimulate the proliferation of neighboring stem/
progenitor cells [2,4]. Shackleton et al. [10] demonstrated
that a single, self-renewing Lin-CD29hiCD24+ cell could
repopulate a cleared mammary fat pad. Further analysis of
this basal population revealed that these cells were
exclusively ERα-negative, but did express proliferating cell
nuclear antigen and EGFR [11]. Recent studies by Smalley
and coworkers [12] have also demonstrated that a
subpopulation of ERα-positive epithelial cells lacked in vivo
stem cell activity. Limiting dilution transplantation revealed
that CD24lo ERα-negative basal epithelial cells displayed the
highest stem cell activity, while ERα-positive luminal cells
exhibited very little stem cell activity, as defined by mammary
repopulating units [12].
These studies raise the following critical question: how can a
single ERα-negative stem cell give rise to a complete,
functional ductal tree when transplanted into the cleared
mammary fat pad? Wicha and colleagues [13] have proposed
that ERα-negative stem cells give rise to undifferentiated
steroid receptor-positive cells, which proliferate in response
to estrogen and secrete paracrine factors that regulate the
proliferation and differentiation of adjacent ER-negative cells.
In accordance with this model and the findings of Brisken and
coworkers, we propose that an ERα-negative basal stem cell
may divide asymmetrically once to give rise to a luminal ERα-
positive progenitor cell. In response to estrogen stimulation,
the resulting ERα-positive cell may secrete paracrine factors,
such as AREG or growth hormone, that can feedback on
ERα-negative stem cells (Figure 1). In addition, those para-
crine factors may stimulate the proliferation and/or differen-
tiation of adjacent ERα-negative and ERα-positive progenitor
cells. Finally, epithelial-derived AREG, for example, may bind
EGFR on more differentiated, neighboring stromal cells that
induce other local growth factors, resulting in massive
proliferation during ductal morphogenesis (see Figure 3 of [3]).
Amphiregulin and breast cancer
What implications do these studies of normal mammary
ductal morphogenesis have for our understanding of human
breast cancer? Specifically, how do quiescent ERα-positive
epithelial cells become proliferative in hormone-dependent
breast cancers? Some insights have come from recent
studies by Allred and coworkers [14], who used DNA
microarrays to determine differences in gene expression
between terminal duct lobular units (TDLUs) and hyperplastic
enlarged lobular units (HELUs). HELUs result from abnormal
enlargement of TDLUs and are the earliest histologically
identifiable lesions with premalignant potential observed
during the progression from normal ductal epithelium to
hormone-dependent breast cancer. Interestingly, HELUs,
Figure 1
Mammary stem cells and the estrogen receptor (ER). ER-negative stem
cells may asymmetrically divide to self-renew and to give rise to
undifferentiated ER-positive progenitor cells. In response to estrogens,
ER-positive progenitors secrete paracrine factors, such as
amphiregulin (AREG) that can influence the proliferation and/or
differentiation of ER-negative stem cells. E2, estradiol.Page 3 of 3
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which were previously shown to contain highly proliferative
cells with elevated ERα expression, showed a ten-fold
increase in AREG compared to normal TDLUs. This increase
was accompanied by a 14-fold decrease in epidermal growth
factor, while the expression of EGFR was unchanged. These
results suggest an early switch in EGFR ligands that may be
important for breast cancer initiation [14]. Whether this
switch is mediated by estrogen remains to be determined.
AREG is overexpressed in most ERα-positive primary breast
tumors, and EGFR expression in breast cancer has been
associated with poor prognosis and resistance to hormone
therapy [15]. Using a three-dimensional culture model of
human breast cancer progression, Bissell and colleagues
[16] recently described an ADAM17-dependent autocrine
loop that induced a malignant phenotype. Importantly, this
phenotype was reversed by inhibiting ADAM17, which
consequently halted signals exerted by AREG and trans-
forming growth factor (TGF)-α, another member of the EGFR
ligand family. Bissell proposed that ADAM17 is a key
protease involved in subverting the dependence on pro-
liferative signals in breast cancer progression, and that
targeting ADAM17 activity may provide an effective therapy
for those breast cancers with deregulated EGFR signaling
[16]. It should be noted, however, that the particular ligand
that is important in EGFR-overexpressed breast cancers
remains controversial. Other studies have suggested that
TGF-α, rather than AREG, plays a key role in breast cancer
progression [17]. In support, Bissell and coworkers [16]
showed a direct correlation between ADAM17 and TGF-α in
a panel of human breast tumors, which was predictive of poor
prognosis. Thus, it is clear that further investigation is
required to elucidate the mechanistic role of AREG and/or
TGF-α in hormone-dependent breast cancers.
Conclusions
Estrogen-mediated proliferation is fundamental to mammary
gland development and breast tumorigenesis. Recent studies
have established an important relationship between ERα,
AREG, proliferation and breast cancer. AREG is a key
paracrine factor that not only mediates ductal elongation, but
may also play an important role in mammary stem cell self-
renewal and differentiation. Elucidating the molecular
mechanisms that regulate AREG signaling in the mammary
gland, including the switch from estrogen-mediated paracrine
events to an autocrine pathway, will be required for a
complete understanding of the early events in breast cancer
progression.
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